Human exposure assessment: finding out what's getting in. by Wakefield, J
I
A s the number of people dying
worldwide from noncommunicable
diseases such as cancer and heart
disease continues to rise, being able to mea-
sure and qualify people's exposure to harm-
ful environmental agents is becoming
increasingly important. Exposure assess-
ment is emerging as a scientific field thanks
in large part to revolutionary advances in
genetics, molecular biology, and microenvi-
ronmental and personal measurement tech-
nology. "As the methods ofexposure assess-
ment become more robust, sensitive, and
inexpensive, they will dramatically change
the field," says Richard Jackson, director of
the National Center for Environmental
Health at the Centers for Disease Control
and Prevention inAtlanta, Georgia.
Jackson was one ofa group ofmore than
400 government, academic, and industry sci-
entists and policy makers that met in
September 1999 to discuss the role of
human exposure ass ent et
tion of environmental disease. "When we're
talking about creating a new science for the
field ofexposure assessment, what we're real-
ly talking about is new ways of understand-
ing the dose-response relationship necessary
to understand risk assessment," -ys Samuel
Wilson, deputy director ofthe NIEHS.
"Exposure analysis provides the bridge ...
between traditional environmental science
and toxicology and epidemiology," says Paul
Lioy, deputy director of the Environmental
and Occupational Health Sciences Institute
in Piscataway, New Jersey. According to
Lioy, researchers are developing an entirely
new conceptual framework to understand
how environmental exposures affect public
health.
However, George Lucier, director of the
NIEHS's Environmental Toxicology
Program, considers it a stretch to call expo-
sure assessment a new science and says the
field just needs some reinventing. "It is an
old science that has languished, that hasn't
gotten the support it deserved," he says. But
he acknowledges that the discipline needs to
be rethought, especially in terms of disease
and determining individual sensitivity.
Whether exposure assessment is emerg-
ing as a newly defined field or merely a rein-
vented one, a new paradigm to link human
exposure assessment to disease is crystalliz-
ing. Most experts agree that the key lies in
linking the many new tools being developed
for examining exposure to hypothesis-driven
research.
Researchers can approach the expo-
sure-disease relationship from two directions.
From the exposure end they can learn how a
person's exposure to a chemical may lead to
disease. From examining a disease trend in the
population or a subpopulation, they can work
backward to exposure. "There's a recognition
that both observational kinds of research for
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providing exposure databases and hypothesis-
driven research are important," Lucier says.
Programs such as the National Human
Exposure Assessment Survey (which is design-
ing a national exposure surveillance system)
and the National Health and Nutrition
Examination Survey (apioneering interagency
program to generate blood and urine data for
estimating exposure of the U.S. population)
provide an important foundation for generat-
ing reasonable hypotheses to test, he says. The
National Occupational Exposure Survey, a
related program, is developing an occupation-
al exposuredatabase.
Assessing Exposure in the
Environment andthe Body
Most experts agree that inadequate informa-
tion currently exists regarding the type, pat-
tern, and magnitude ofhuman exposure to
chemicals through food, the workplace, and
the environment. Many believe that critical
knowledge gaps will take years to fill.
"Human exposure assessment is often the
weakest link in risk assessment," says NIEHS
director Kenneth Olden. This weakness
restricts the public health community's abili-
ty to evaluate low-dose effects ofexposures to
chemicals and identify at-risk populations. It
also restricts researchers' ability to design
studies to evaluate exposure-response rela-
tionships and study gene-environment inter-
actions, he says.
"Adverse health outcome is a function of
toxicity and exposure, both duration and
intensity," Olden says. He explains that envi-
ronmental monitoring, which determines
what's in the air, soil, food, and water, is not
equivalent to individual exposure, which
reflects concentrations ofchemicals and envi-
ronmental agents that actually are in people's
bodies and their resulting effects.
Traditionally, the responsibility ofmoni-
toring chemicals in the environment and in
people's bodies has been scattered across gov-
ernment agencies. Operating in isolation
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Yet even the reigning individual exposure
assessment tools-biomarkers, physical
quantifiable changes that evidence expo-
sure-have a long way to go. Alone, bio-
markers do not necessarily provide enough
information for valid risk assessments to be
formulated. For a long time, Lioy, like many
others, believed biomarkers would be the
gold standard. The precision with which
researchers became capable ofdetecting sub-
tle biochemical and molecular changes
offered great promise. For example, after
exposure to a carcinogen such as vinyl chlo-
ride, a mutant form of a protein may be
found in the bloodstream of an individual
even though no tumors are detected in tis-
sues. But Lioy has since changed his stance,
acknowledging that "biomarkers are one tool
in a big toolbox that includes personal and
microenvironmental measurement, identity
patterns, and predictive models."
In addition, says John D. Groopman,
chair of the oncology department at the
Johns Hopkins University School of Public
Health, "No one biomarker is going to be
totally complete with respect to predicting
disease outcome." There are, says
Groopman, still relatively few biomarkers
that have been brought through a rather
complex process ofvalidation and that sci-
entists can use to obtain reliable information
on how exposure to a suspect agent can
result in a specific health end point-infor-
mation that is valid for exposure assessment
or for risk assessment. A tiered experimental
and human investigation approach is needed
to understand how biomarkers act in differ-
ent populations and environments, he says.
In this context, researchers argue that a
greater emphasis needs to be placed on expo-
sures to children and other potentially sensi-
tive subpopulations.
Moreover, exposure by itself does not
necessarily result in disease. "We have to rec-
ognize that things are not driven by just
exposure alone in terms ofsome ofthese very
long-term outcomes," Groopman says.
"There is certainly an interaction with
respect to the host's genetic susceptibility
that is playing an important role."
The fact that gene-environment interac-
tions profoundly affect whether an environ-
mental exposure may lead to disease is a rela-
tively new factor in the equation. Says
Groopman, "We're entering a completely
new world now, a world where our genetic
understanding is leading to the development
of an incredible panoply of early detection
disease biomarkers. What's being developed
now as a result ofthe genetic revolution, the
Human Genome Project, and . . . the
Environmental Genome Project is the fact
-Lynn Goldman
that we are beginning to identify individuals
at subclinical disease state [before a disease is
manifested], and we need to now integrate
into our paradigm what role exposure will
play in either exacerbating or blunting the
blossoming of that disease state when it
becomes a clinically defined identity." The
Environmental Genome Project is a multi-
agency effort to systematically identify the
alleles of some 200 environmental suscepti-
bility genes in the U.S. population.
RiskAssessment and Policy
"Our ability to make these measurements,
do these analyses, understand the meaning
of these biomarkers really only has impor-
tance ifwe can utilize these data in a public
health setting in order to reduce morbidity
and mortality ofdisease in individuals," says
Groopman.
Lioy agrees: "We need to know whether
body burdens of lead, polychlorinated
biphenyls, dioxins, volatile organics, and
other air and water pollutants are increasing,
remaining at the same levels, or decreasing as
regulations meant to decrease the levels of
these chemicals in the environment are
designed and implemented." In general, the
community needs to do a better job ofdeter-
mining what works in reducing human
exposure. Lucier says, "Ifit doesn't result in
a reduction in disease then it hasn't been
successful."
Policy makers are confident more
answers will be coming in the next decade.
"The field of exposure assessment can
address many ofour most visible health con-
cerns," Lucier says. "What's kept it from suc-
ceeding in the past has largely been people's
inability to worktogethereffectively."
The NIEHS hopes to change that with
new interagency initiatives in exposure
assessment. The idea is to coordinate tradi-
tional research fields across agencies. In
cooperation with the Centers for Disease
Control and Prevention and the EPA, Olden
hopes to dramatically enhance both the tech-
nological sophistication of exposure assess-
ment and the use ofexposure assessment in
the prevention ofhuman disease.
"There's a recognition that a multidisci-
plinary approach is required," Lucier says.
"Many ofthe needed pieces are in place, but
they need to be put together through inter-
agency initiatives." And an interagency fund-
ing initiative would surelyhelp, he adds. The
federal government spends a trillion dollars
each year on the treatment ofdisease, but the
importance of good public health policy
based on sound environmental science can
get lost in the figures. Interagency initiatives,
researchers argue, will link a broader cache of
hypothesis-driven research to exposure assess-
ment and make limited dollars go farther.
To make it happen, more researchers and
new methods and tools are needed to stimu-
late the field. Without effective use ofexperi-
mental data, the decisions that can be made
about chemical exposures are limited. "There
is a frustration in the whole regulatory arena
that many epidemiological studies for expo-
sure assessment don't easily lend themselves
to the risk assessment mantra," says
Goldman, "and the exposure assessment
information doesn't readily lend itselfto out-
comes research." Advances, especially in ana-
lytical technology and molecular biology,
may change that. And, says Lucier, "We
need cross-training so our researchers will
think like a toxicologist and an epidemiolo-
gist at the same time. We don't have those
kind ofpeople trained today."
Experts predict that in the future
improved exposure assessment will play a
leading role in the prevention of environ-
mental disease. Says Jackson, "Ten years
from now in the field of environmental
health, it will seem strange to talk about
exposure without looking at the actual
human dose."
JulieWakefield
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Exposure monitoring is equivalent to the
right to know. The key to assessment is
surveillance of disease and exposure.
[Wle need to now integrate into our
paradigm what role exposure will play in
either exacerbating or blunting the blossoming
of [a] disease state.
-John D. Groopman
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